yubK Antibody

What is yubK Antibody and what is its target specificity?

yubK Antibody is a rabbit polyclonal antibody designed to recognize the yubK protein (Uniprot ID: Q9JMR4) from Escherichia coli (strain K12) . This antibody has been developed as part of custom antibody collections for research applications, particularly focusing on bacterial proteins. The antibody is typically affinity-purified using the recombinant Escherichia coli yubK protein as the immunogen .

What are the validated applications for yubK Antibody?

Based on available technical specifications, yubK Antibody has been validated for the following applications:

• Enzyme Immunoassay (EIA)

• Enzyme-Linked Immunosorbent Assay (ELISA)

• Western Blot (WB)

How should researchers store and handle yubK Antibody?

For optimal stability and performance, follow these storage guidelines:

• Upon receipt, store at -20°C or -80°C to maintain long-term stability

• Avoid repeated freeze-thaw cycles that can degrade antibody performance

• For short-term usage (within 1 month), aliquot and store at 4°C

• The antibody is typically supplied in a buffer containing 50% glycerol, 0.01M PBS (pH 7.4), and preservatives like 0.03% Proclin 300

What minimum validation steps should be performed before using yubK Antibody in experiments?

Based on current antibody validation standards, researchers should perform the following minimum validation steps:

Research indicates that ~50% of commercial antibodies may fail basic validation standards, making this step critical for reliable results .

How can researchers implement genetic controls to validate yubK Antibody specificity?

For rigorous validation of yubK Antibody specificity, genetic knockout (KO) controls are considered superior to other validation methods. Based on systematic antibody validation research:

• Develop or acquire E. coli K12 yubK knockout strains:

  • Either through targeted gene deletion or CRISPR-based genome editing

  • Commercial KO strains may be available from bacterial repositories

• Parallel testing methodology:

  • Run wild-type and KO samples side-by-side under identical conditions

  • For Western blot: Look for absence of specific band in KO sample

  • For ELISA: Compare signal between WT and KO lysates

• Quantitative assessment:

  • Calculate signal-to-noise ratio between WT and KO samples

  • A high-performing antibody should show >5-fold difference

Studies have shown that genetic approaches using KO cells as validation controls are significantly more reliable than orthogonal approaches, with 89% of antibodies validated by genetic approaches correctly identifying their targets versus only 80% validated by orthogonal methods .

What experimental strategies can minimize false positive results when using yubK Antibody?

To minimize false positives and ensure reliable experimental outcomes, implement these advanced strategies:

• Multiple detection methods:

  • Validate findings using at least two different antibody-based techniques

  • Complement with non-antibody methods (e.g., mass spectrometry)

• Blocking peptide competition assay:

  • Pre-incubate antibody with excess recombinant yubK protein

  • Loss of signal confirms specificity for target epitope

• Cross-adsorption controls:

  • Pre-adsorb antibody with lysates from yubK KO strains

  • Removes antibodies that might bind to other bacterial proteins

• Quantitative signal analysis:

  • Use digital imaging and analysis software to quantify signal intensities

  • Establish clear thresholds for positive vs. negative results based on controls

Research has shown that approximately 20-30% of published figures may be generated using antibodies that do not recognize their intended target, highlighting the importance of these validation steps .

How can researchers quantify yubK Antibody persistence in cell-based assays?

For experiments requiring quantification of antibody persistence (e.g., in time-course studies), implement this validated methodology based on established protocols:

• Experimental setup with four parallel conditions:

  • Live proliferative cells

  • Live non-proliferative cells (treated with mitomycin C)

  • Fixed cells (pre-treatment)

  • Fixed cells/antibody (post-antibody treatment)

• Standard protocol:

  • Seed cells at 6000-7000 cells/well in 96-well plates

  • Apply appropriate treatments (fixation, antimitotic)

  • Block cells with 3% BSA in HBSS for 1 hour at 37°C

  • Incubate with primary yubK Antibody at optimized concentration

  • At each time point, apply fluorescent secondary antibody (1:500 dilution)

  • Counterstain nuclei with Hoechst dye (1:500)

  • Image using fluorescence microscopy with 12 images per well

• Data analysis:

  • Calculate mean fluorescence intensity at each time point

  • Plot antibody persistence curve

  • Determine half-life of antibody signal under different conditions

This approach allows for comprehensive assessment of antibody persistence while distinguishing between various removal mechanisms .

What are the optimal protocols for using yubK Antibody in Western blot experiments?

Based on validated protocols for bacterial protein antibodies, here is an optimized Western blot protocol for yubK Antibody:

Sample preparation:

• Bacterial culture: Grow E. coli to mid-log phase (OD600 = 0.5-0.8)

• Harvest 1ml culture by centrifugation at 5000 × g for 5 minutes

• Resuspend in SDS sample buffer and boil for 5 minutes

• Load 10-20μg total protein per lane

Blotting procedure:

• Separate proteins on 12% SDS-PAGE gel

• Transfer to PVDF membrane (0.2μm pore size preferred)

• Block with 5% non-fat milk in TBST for 1 hour at room temperature

• Incubate with yubK Antibody at 1:500 to 1:1000 dilution in blocking buffer overnight at 4°C

• Wash 3× with TBST, 5 minutes each

• Incubate with HRP-conjugated anti-rabbit secondary antibody (1:5000) for 1 hour

• Wash 3× with TBST, 5 minutes each

• Develop using ECL substrate and image using appropriate system

Critical controls to include:

• Positive control: Recombinant yubK protein (200ng)

• Negative control: E. coli lysate from yubK knockout strain

• Loading control: Anti-16S rRNA or anti-RNA polymerase antibody

Research indicates that recombinant antibodies generally outperform both monoclonal and polyclonal antibodies in Western blot applications, but a well-validated polyclonal like yubK Antibody can provide excellent results when properly optimized .

How should researchers approach quantitative ELISA development using yubK Antibody?

For development of a quantitative ELISA to detect yubK protein:

Protocol optimization:

• Coating: 100μl of capture antibody at 1-10μg/ml in carbonate buffer (pH 9.6), overnight at 4°C

• Blocking: 300μl of 3% BSA in PBS for 1 hour at 37°C

• Sample incubation: 100μl of samples and standards in 1% BSA/PBS for 2 hours at 37°C

• Detection: 100μl of yubK Antibody (1:10,000 dilution recommended for ELISA) for 1 hour at 37°C

• Secondary antibody: 100μl of HRP-conjugated anti-rabbit IgG (1:5000) for 1 hour at RT

• Substrate: 100μl TMB solution for 15-30 minutes, protected from light

• Stop reaction: 50μl of 2M H₂SO₄

• Read absorbance at 450nm with 570nm correction

Standard curve preparation:

• Use recombinant yubK protein

• Prepare 2-fold serial dilutions ranging from 0-1000ng/ml

• Include at least 8 concentration points for accurate curve fitting

Data analysis:

• Use 4-parameter logistic regression for curve fitting

• Determine limit of detection (LOD) and limit of quantification (LOQ)

• Calculate inter- and intra-assay coefficients of variation (CV < 15% is acceptable)

How can researchers design experiments to distinguish between specific yubK detection and potential cross-reactivity?

To rigorously address potential cross-reactivity concerns, implement this systematic experimental design:

• Comprehensive competition assays:

  • Pre-incubate yubK Antibody with increasing concentrations of recombinant yubK protein

  • Pre-incubate with structurally similar bacterial proteins

  • Analyze signal reduction patterns to determine binding specificity

• Cross-species reactivity testing:

  • Test antibody against lysates from multiple E. coli strains

  • Test against closely related Enterobacteriaceae family members

  • Quantify relative binding affinity to identify potential cross-reactivity

• Epitope mapping experiments:

  • Generate overlapping peptide fragments of yubK protein

  • Identify specific epitope(s) recognized by the antibody

  • Perform in silico analysis to identify similar epitopes in other proteins

• Multi-technique validation:

  • Compare results between Western blot, ELISA, and immunofluorescence

  • Technique-specific cross-reactivity may indicate different epitope accessibility

  • Discrepancies between techniques can reveal potential non-specific binding

How might yubK Antibody be integrated into antibody nanocage technology for enhanced detection sensitivity?

Recent advances in antibody nanocage (AbC) technology offer opportunities to enhance yubK Antibody performance:

• Computational design approach:

  • yubK Antibody can be incorporated into symmetric assemblies using AbC technology

  • This creates homogeneous, structurally well-defined nanocages with precise architectures

  • These structures can enhance detection sensitivity by increasing valency

• Implementation methodology:

  • Rigorously fuse yubK Antibody to cyclic oligomers using helical spacer domains

  • Optimize junction regions for structural stability

  • Express synthetic genes encoding the designs in E. coli cultures

  • Characterize resulting nanocages using small-angle X-ray scattering and electron microscopy

• Expected benefits:

  • Increased avidity through multivalent presentation

  • Enhanced signal-to-noise ratio in detection assays

  • Improved sensitivity for low-abundance target detection

  • Potential for multiplexed detection platforms

This cutting-edge approach represents a significant advance over traditional antibody-based detection methods and could substantially improve yubK protein detection limits.

What are the best practices for evaluating batch-to-batch consistency of yubK Antibody?

Maintaining experimental reproducibility requires rigorous batch-to-batch consistency validation:

• Establish reference standards:

  • Create a "gold standard" reference batch with extensively characterized properties

  • Aliquot and store at -80°C to maintain long-term stability

  • Use as comparative standard for all new batches

• Multi-parameter characterization protocol:

  Parameter	Method	Acceptance Criteria
  Titer	ELISA against recombinant yubK	Within 2-fold of reference
  Specificity	Western blot pattern analysis	Identical band pattern to reference
  Sensitivity	Limit of detection determination	Within 20% of reference value
  Purity	SDS-PAGE	>90% pure IgG band
  Immunoreactivity	BioLayer Interferometry	Kd within 30% of reference

• Digital data repository:

  • Maintain comprehensive digital records of each batch's performance

  • Include raw data, analysis methods, and comparative results

  • Document Research Resource Identification (RRID) for traceability

Studies show that inadequate batch-to-batch validation contributes significantly to irreproducibility in antibody-based research, making this step critical for reliable long-term studies .

How can researchers integrate yubK Antibody into multiplexed detection systems for bacterial protein analysis?

To develop sophisticated multiplexed detection systems incorporating yubK Antibody:

• Antibody labeling strategies:

  • Direct conjugation with distinct fluorophores (e.g., Alexa Fluor 488, 555, 647)

  • Biotinylation for streptavidin-based detection systems

  • Integration with quantum dot (QD) labeled LFIA systems for rapid detection

• Multiplexed platform development:

  • Microarray-based detection: Spot multiple antibodies against bacterial proteins

  • Multiplexed bead-based assays: Couple yubK Antibody to uniquely coded beads

  • Microfluidic channels with spatial separation of capture antibodies

• Data analysis and normalization:

  • Employ multi-parameter calibration curves with recombinant standards

  • Implement machine learning algorithms for signal pattern recognition

  • Use Random Forest models to interpret complex multiplexed signals

• Validation strategy:

  • Test with defined mixtures of recombinant proteins at known ratios

  • Validate with complex bacterial lysates of known composition

  • Compare results with single-plex detection for each target protein

Research demonstrates that QD-labeled LFIA methods can produce rapid results (~10 minutes) with high sensitivity and specificity, making them excellent platforms for multiplexed bacterial protein detection incorporating yubK Antibody .